Cargando…

Liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study

BACKGROUND: Emerging evidence highlights that targeting the gut microbiota could be an interesting approach to improve alcohol liver disease due to its important plasticity. This study aimed to evaluate the effects of inulin supplementation on liver parameters in alcohol use disorder (AUD) patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Amadieu, Camille, Maccioni, Luca, Leclercq, Sophie, Neyrinck, Audrey M., Delzenne, Nathalie M., de Timary, Philippe, Stärkel, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062816/
https://www.ncbi.nlm.nih.gov/pubmed/35490461
http://dx.doi.org/10.1016/j.ebiom.2022.104033
_version_ 1784699031358799872
author Amadieu, Camille
Maccioni, Luca
Leclercq, Sophie
Neyrinck, Audrey M.
Delzenne, Nathalie M.
de Timary, Philippe
Stärkel, Peter
author_facet Amadieu, Camille
Maccioni, Luca
Leclercq, Sophie
Neyrinck, Audrey M.
Delzenne, Nathalie M.
de Timary, Philippe
Stärkel, Peter
author_sort Amadieu, Camille
collection PubMed
description BACKGROUND: Emerging evidence highlights that targeting the gut microbiota could be an interesting approach to improve alcohol liver disease due to its important plasticity. This study aimed to evaluate the effects of inulin supplementation on liver parameters in alcohol use disorder (AUD) patients (whole sample) and in a subpopulation with early alcohol-associated liver disease (eALD). METHODS: Fifty AUD patients, hospitalized for a 3-week detoxification program, were enrolled in a randomized, double-blind, placebo-controlled study and assigned to prebiotic (inulin) versus placebo for 17 days. Liver damage, microbial translocation, inflammatory markers and 16S rDNA sequencing were measured at the beginning (T1) and at the end of the study (T2). FINDINGS: Compared to placebo, AST (β = 8.55, 95% CI [2.33:14.77]), ALT (β = 6.01, 95% CI [2.02:10.00]) and IL-18 (β = 113.86, 95% CI [23.02:204.71]) were statistically significantly higher in the inulin group in the whole sample at T2. In the eALD subgroup, inulin supplementation leads to specific changes in the gut microbiota, including an increase in Bifidobacterium and a decrease of Bacteroides. Despite those changes, AST (β = 14.63, 95% CI [0.91:28.35]) and ALT (β = 10.40, 95% CI [1.93:18.88]) at T2 were higher in the inulin group compared to placebo. Treatment was well tolerated without important adverse events or side effects. INTERPRETATION: This pilot study shows that 17 days of inulin supplementation versus placebo, even though it induces specific changes in the gut microbiota, did not alleviate liver damage in AUD patients. Further studies with a larger sample size and duration of supplementation with adequate monitoring of liver parameters are needed to confirm these results. Gut2Brain study: https://clinicaltrials.gov/ct2/show/NCT03803709 FUNDING: Fédération Wallonie-Bruxelles, FRS-FNRS, Fondation Saint-Luc.
format Online
Article
Text
id pubmed-9062816
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90628162022-05-04 Liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study Amadieu, Camille Maccioni, Luca Leclercq, Sophie Neyrinck, Audrey M. Delzenne, Nathalie M. de Timary, Philippe Stärkel, Peter EBioMedicine Articles BACKGROUND: Emerging evidence highlights that targeting the gut microbiota could be an interesting approach to improve alcohol liver disease due to its important plasticity. This study aimed to evaluate the effects of inulin supplementation on liver parameters in alcohol use disorder (AUD) patients (whole sample) and in a subpopulation with early alcohol-associated liver disease (eALD). METHODS: Fifty AUD patients, hospitalized for a 3-week detoxification program, were enrolled in a randomized, double-blind, placebo-controlled study and assigned to prebiotic (inulin) versus placebo for 17 days. Liver damage, microbial translocation, inflammatory markers and 16S rDNA sequencing were measured at the beginning (T1) and at the end of the study (T2). FINDINGS: Compared to placebo, AST (β = 8.55, 95% CI [2.33:14.77]), ALT (β = 6.01, 95% CI [2.02:10.00]) and IL-18 (β = 113.86, 95% CI [23.02:204.71]) were statistically significantly higher in the inulin group in the whole sample at T2. In the eALD subgroup, inulin supplementation leads to specific changes in the gut microbiota, including an increase in Bifidobacterium and a decrease of Bacteroides. Despite those changes, AST (β = 14.63, 95% CI [0.91:28.35]) and ALT (β = 10.40, 95% CI [1.93:18.88]) at T2 were higher in the inulin group compared to placebo. Treatment was well tolerated without important adverse events or side effects. INTERPRETATION: This pilot study shows that 17 days of inulin supplementation versus placebo, even though it induces specific changes in the gut microbiota, did not alleviate liver damage in AUD patients. Further studies with a larger sample size and duration of supplementation with adequate monitoring of liver parameters are needed to confirm these results. Gut2Brain study: https://clinicaltrials.gov/ct2/show/NCT03803709 FUNDING: Fédération Wallonie-Bruxelles, FRS-FNRS, Fondation Saint-Luc. Elsevier 2022-04-28 /pmc/articles/PMC9062816/ /pubmed/35490461 http://dx.doi.org/10.1016/j.ebiom.2022.104033 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Amadieu, Camille
Maccioni, Luca
Leclercq, Sophie
Neyrinck, Audrey M.
Delzenne, Nathalie M.
de Timary, Philippe
Stärkel, Peter
Liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study
title Liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study
title_full Liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study
title_fullStr Liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study
title_full_unstemmed Liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study
title_short Liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study
title_sort liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: a pilot randomized, double-blind, placebo-controlled study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062816/
https://www.ncbi.nlm.nih.gov/pubmed/35490461
http://dx.doi.org/10.1016/j.ebiom.2022.104033
work_keys_str_mv AT amadieucamille liveralterationsarenotimprovedbyinulinsupplementationinalcoholusedisorderpatientsduringalcoholwithdrawalapilotrandomizeddoubleblindplacebocontrolledstudy
AT maccioniluca liveralterationsarenotimprovedbyinulinsupplementationinalcoholusedisorderpatientsduringalcoholwithdrawalapilotrandomizeddoubleblindplacebocontrolledstudy
AT leclercqsophie liveralterationsarenotimprovedbyinulinsupplementationinalcoholusedisorderpatientsduringalcoholwithdrawalapilotrandomizeddoubleblindplacebocontrolledstudy
AT neyrinckaudreym liveralterationsarenotimprovedbyinulinsupplementationinalcoholusedisorderpatientsduringalcoholwithdrawalapilotrandomizeddoubleblindplacebocontrolledstudy
AT delzennenathaliem liveralterationsarenotimprovedbyinulinsupplementationinalcoholusedisorderpatientsduringalcoholwithdrawalapilotrandomizeddoubleblindplacebocontrolledstudy
AT detimaryphilippe liveralterationsarenotimprovedbyinulinsupplementationinalcoholusedisorderpatientsduringalcoholwithdrawalapilotrandomizeddoubleblindplacebocontrolledstudy
AT starkelpeter liveralterationsarenotimprovedbyinulinsupplementationinalcoholusedisorderpatientsduringalcoholwithdrawalapilotrandomizeddoubleblindplacebocontrolledstudy